KUN-HUEI YEHYEN-SHEN LUHsiao C.-H.ANN-LII CHENG2021-09-012021-09-0120030250-7005https://www.scopus.com/inward/record.uri?eid=2-s2.0-0842343492&partnerID=40&md5=42feb91a8f7dbece5f806f3bc9713f16https://scholars.lib.ntu.edu.tw/handle/123456789/580415A 46-year-old female patient suffered from uterine malignant leiomyosarcoma. Ten months after abdominal subtotal hysterectomy, multiple lung, bone and spine metastases developed. She received 3 cycles of infusional ADI chemotherapy (adriamycin 60 mg/m2, 96-hour i.v. infusion, dacarbazine 500 mg/m2, 96-hour i.v. infusion and ifosfamide 5,000 mg/m2, 72-hour i.v. infusion, repeated every 3 weeks), but the metastatic tumors progressed. An empirical ADI-TAM chemotherapy which incorporated high-dose tamoxifen (TAM) (150 mg/m2/day, in 4 divided doses) into the original ADI regimen was applied from the fourth cycle. High-dose tamoxifen consisted of 240 mg/day for 4 days during chemotherapy and 40 mg/day between cycles. Good partial response with nearly total tumor reduction was achieved after 3 cycles of ADI-TAM therapy. The excellent tumor response by simple addition of high-dose tamoxifen into a previously inactive ADI regimen advocates further investigation for the development of chemotherapy in metastatic uterine leiomyosarcoma.[SDGs]SDG3antineoplastic agent; carmustine; cisplatin; cytochrome P450; dacarbazine; docetaxel; doxorubicin; gemcitabine; glycoprotein P; ifosfamide; mesna; multidrug resistance protein; tamoxifen; abdominal hysterectomy; adult; article; brain metastasis; cancer chemotherapy; cancer combination chemotherapy; cardiotoxicity; case report; drug infusion; drug megadose; female; human; leiomyosarcoma; lung metastasis; multidrug resistance; nephrotoxicity; postoperative care; priority journal; spine metastasis; treatment outcome; uterus cancer; uterus sarcoma; uterus tumor; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Ifosfamide; Leiomyosarcoma; Middle Aged; Neoplasm Metastasis; Tamoxifen; Uterine Neoplasmsjournal article149865912-s2.0-0842343492